Video

What Is Janssen Doing To Increase Patient Diversity In Trials?

Source: Clinical Leader
20_11_CLL_PatientDiversity_1920x1080_Clip6

Patient diversity remains a problem in clinical trials. Although FDA-approved medicines serve a diverse population of Americans, participation in clinical trials remains predominantly white and male.

In this webinar segment, Cassandra Smith, director of diversity & inclusion in clinical trials for Janssen, discusses what Janssen is doing to increase recruitment of minority patients. The company started with a strategy to oversee the diversity effort. That strategy includes taking a close look at trial protocols, barriers to participation, and a careful site selection process. The strategy also involves sharing information about clinical research via educational outreach. Smith also discusses the factors that made the company’s LOTUS trial successful in recruiting women of color.

VIEW THE VIDEO!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: